

Open Lecture
PERSONALIZING CANCER THERAPY: FROM LABS TO TRIALS TO POLICY
Elizabeth A. Eisenhauer, MD, FRCP

Wednesday, 12th October 2011
5.00 – 6.00 pm

Lecture Hall, Centre Hospitalier de Luxembourg (CHL),
4, rue Ernest Barblé, L-1210 Luxembourg

The Integrated BioBank of Luxembourg (IBBL) and the Laboratory of Experimental Hemato-Oncology of the Centre de Recherche Public – Santé (CRP-Santé) are delighted to invite you to an exclusive open lecture entitled *Personalizing Cancer Therapy: From Labs to Trials to Policy* presented by Elizabeth A. Eisenhauer, MD, FRCP on Wednesday 12th October 2011 from 5.00 to 6.00 pm in the Lecture Hall of the Centre Hospitalier de Luxembourg (CHL), Luxembourg.

ABOUT THE LECTURE

21st century cancer therapy is increasingly focused on identifying patient and/or tumour selection biomarkers that will drive treatment decisions and optimize outcomes. However, there are important gaps to be bridged between lab, clinic and policy – what tests will offer the greatest impact? which are cost effective and addressing real clinical problems? And what research must be undertaken during biomarker and therapeutics development to provide the data required to assess cost effectiveness? A case for real world testing of new approaches will be made as one example of engagement of policy makers and practitioners in designing those studies needed to ensure appropriate uptake of new technologies into practice.

ABOUT THE SPEAKER



Elizabeth A. EISENHAUER, MD, FRCP

Obtained her MD from Queen's University Kingston, Canada in 1976 and subsequently completed Royal College of Physicians and Surgeons (Canada) training in both Internal Medicine and Hematology. In 1982 she became Director of the Investigational New Drug Program (IND) of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) where her major responsibilities lie in identifying and bringing into clinical trial novel cancer agents. She is also a Professor in the Department of Oncology at Queen's University.

Her major research interest has been the evaluation of new anti-cancer agents. Through her work in the IND Program at NCIC CTG coordinating over 170 phase I, II and III trials carried out in institutions in Canada, the US and Europe. These have included some of the first trials of paclitaxel and docetaxel, studies of topotecan, gemcitabine, various targeted antisense agents, angiogenesis inhibitors and small molecule signaling inhibitors.

Dr. Eisenhauer has also served on committees of many national and international bodies including the National Cancer Institute of Canada, the Canadian Cancer Society, the Royal College of Physicians and Surgeons of Canada, the European Organization for Research and Treatment of Cancer, the American Society of Clinical Oncology and the US National Cancer Institute.

In 1998 she was the Michel Clavel Award lecturer at the NCI-EORTC Symposium on New Drugs in Cancer Treatment held in Amsterdam. In 2002 she was awarded the O. Harold Warwick Prize by the National Cancer Institute of Canada that recognizes a scientist whose research has had a major impact in Cancer Control in Canada. In 2010 The Society of Gynecologic Oncology of Canada (GOC) presented Dr. Eisenhauer with the GOC Presidential Medal Award in recognition of her outstanding contributions to gynecologic oncology in Canada and Abroad.

In 2002 she was appointed to the Board of Directors of the National Cancer Institute of Canada and from June 2006-February 2009 she was President of NCIC. As of September 2008, in addition to continuing her role as Director of the NCIC CTG IND program, she assumed the position of Chair of the Research Advisory Group of the Canadian Partnership Against Cancer, the federally funded agency charged with implementing the Canadian Strategy for Cancer Control. In this role she is co-chairing the Canadian Cancer Research Alliance, the alliance of Canada's major cancer research funders.

HOW TO ATTEND?

If you wish to attend, please print out this invitation and bring it with you to the event. Entrance is free of charge !

We do hope you are able to join us.

Yours sincerely,



Arnaud d'Agostini
Communications Manager

INTEGRATED **BIOBANK**
OF LUXEMBOURG
For Next Generation Healthcare

Address: 6, rue Nicolas Ernest Barblé, L-1210, Luxembourg (New!)
Tel: + 352 27 44 64 - 1
Fax: 352 27 44 64 - 64
E-mail: arnaud.dagostini@ibbl.lu, events@ibbl.lu
Web: www.ibbl.lu

The Integrated BioBank of Luxembourg (IBBL) is an independent, not-for-profit biobanking and biotechnology foundation
